Stem cell company bit.bio lays off quarter of staff
The British stem cell company bit.bio has reduced its workforce by 25%, impacting most of the therapeutics division, founder and board member Mark Kotter confirmed to Endpoints News. About 150...
View ArticleServier licenses Black Diamond’s RAS- and RAF-targeted drug
Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year as it focused resources on developing a next-generation lung cancer...
View ArticleFlagship's Ampersand gets Eli Lilly's support in $65M Series B
Ampersand Biomedicines, a biotech working on medicines "similar in principle" to antibody-drug conjugates, has secured $65 million in a Series B round. Eli Lilly took part in the funding round...
View ArticleRoche inks $1B+ biobucks deal with Oxford BioTherapeutics for new antibody...
Roche has forged a multiyear partnership with Oxford BioTherapeutics to find new targets for antibody-based cancer treatments with an upfront payment of $36 million. The partners will work together to...
View ArticleUpdated: Immunovant will not take rare disease drug to regulators despite...
Immunovant will not seek approval for its candidate for the autoimmune disorder myasthenia gravis (MG), despite a reasonable showing in its pivotal trial. Instead, the company said Wednesday that it...
View ArticlePfizer fully exits Haleon in $3.3B stake sale
Pfizer will get about $3.3 billion from its final stake sale in Haleon, according to a Wednesday filing with the London Stock Exchange. The New York pharma giant is fully exiting ...
View ArticleRegenxbio shares new Duchenne gene therapy data ahead of big readout next year
Regenxbio has biomarker data on the first patient younger than 4 years old dosed with its Duchenne muscular dystrophy gene therapy, showing that the patient expressed levels of a shortened version of a...
View ArticleAhead of FDA decision, Alnylam faces the big question: Can it make money?
Despite pioneering RNAi drug development and getting four therapies approved, Alnylam still isn’t profitable. That may change as soon as next year. The FDA is expected to decide by Sunday whether to...
View ArticleCargo Therapeutics scraps R&D pipeline, axes bulk of workforce as it looks...
As Cargo Therapeutics looks for a permanent solution to its troubles, the biotech is dropping its remaining clinical programs and laying off the majority of staff in a second round of cuts. The San...
View ArticleTrump’s DOJ rejects effort to shed mifepristone restrictions
President Donald Trump's new administration defended Biden-era restrictions on the abortion pill mifepristone, marking one of the first times it’s voiced its stance in the ongoing lawsuits over the...
View ArticleGilead stock slips as HHS denies reports of HIV funding cuts
Gilead Sciences' stock {$GILD} dropped by more than 3% on Wednesday afternoon amid reports that the US will slash billions in CDC funding for anti-HIV prevention efforts. An HHS spokesperson told...
View ArticleNovartis touts Zolgensma data in older children
Novartis released two Phase 3 datasets on Wednesday that show a new version of its gene therapy Zolgensma led to motor function improvements in patients with spinal muscular atrophy. The company hopes...
View ArticleHow Akido Labs uses AI to run medical visits, from intake to diagnosis
For cardiologist Haritha Alla, a typical day in her Los Angeles-area clinic is ruled by mundane data collection. Patients struggle to fill out intake forms and tend to leave them unfinished. Much of...
View ArticleSanofi to pay $600M upfront for Dren Bio’s bispecific B cell depleter
Sanofi is buying a B cell-depleting antibody developed by Dren Bio as a therapy for cancer and autoimmune diseases. The pharma said on Thursday that it will pay $600 million in ...
View ArticleParatek to acquire Optinose and its nasal spray Xhance
Paratek Pharmaceuticals is expanding beyond antibiotics and infectious disease by paying up to $330 million to acquire Optinose and its drug-device combination for chronic rhinosinusitis (CRS). Paratek...
View ArticleMonte Rosa reports first data for molecular glue program
Monte Rosa Therapeutics reported Phase 1 data Thursday morning for a Novartis-partnered program that the companies believe could change the treatment paradigm for some immune-mediated diseases. Though...
View ArticleIllumina's CEO evolves strategy with multiomics push
SAN DIEGO — At the headquarters of Illumina last week, CEO Jacob Thaysen bounded up a coiled staircase that mimics a DNA strand. The architectural flourish at the company’s campus is a representation...
View ArticleUnitedHealth's Optum Rx to change its payment models
UnitedHealth Group's pharmacy benefit manager Optum Rx is making changes to its payment models. Optum Rx will tweak its payment models in full force by January 2028 to more closely reflect the high...
View ArticleElevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI...
Plus, news about Century Therapeutics, Akebia Therapeutics, Eyenovia, Betaliq, Alvotech, Genenta Science, Aadi Bioscience, and Exicure: Elevation Oncology drops ADC, lays off 70%: The Boston-based drug...
View ArticleMerck to lay off 163 workers in Pennsylvania; Delpharm gets $60M from...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Merck plans to lay off 163 staffers as it closes its facility in...
View Article